📊 CRMD Key Takeaways
Investment Thesis
CorMedix demonstrates exceptional financial health with extraordinary growth (617% revenue YoY, 1009% net income YoY) driven by strong demand for its pharmaceutical products. The company maintains fortress-like balance sheet strength with zero debt, abundant liquidity (2.11x current ratio), and industry-leading profitability margins (88.5% gross, 52.3% net). Exceptional cash generation (55.4% FCF margin, $172.8M free cash flow) provides financial flexibility for reinvestment or shareholder returns.
CRMD Strengths
- Explosive revenue and earnings growth (617% and 1009% YoY respectively) indicating strong product market fit and demand
- Exceptional profitability with 52.3% net margin and 40.2% ROE, well above pharmaceutical industry averages
- Pristine balance sheet: zero debt, $144.8M cash, 2.11x current ratio demonstrating superior financial flexibility
- Outstanding cash flow generation with $172.8M free cash flow and 55.4% FCF margin providing capital allocation optionality
- High interest coverage (9160x) and quick ratio (1.94x) confirm no liquidity or solvency concerns
- Significant insider activity (21 Form 4 filings) suggests confidence from company leadership
CRMD Risks
- Extreme growth rates (617% revenue, 1009% net income) may not be sustainable; requires investigation into growth drivers and market saturation potential
- High concentration of revenue likely tied to specific product(s); product obsolescence or competitive displacement poses significant downside risk
- Pharmaceutical sector regulatory risk including FDA approvals, pricing pressures, and patent cliffs not evident from available metrics
- Rapid growth may mask operational inefficiencies that become apparent during normalization cycles or economic downturns
Key Metrics to Watch
- Year-over-year revenue growth sustainability (normalize from current 617% to realistic long-term rate)
- Gross margin maintenance as company scales (currently 88.5%, watch for manufacturing/supply chain pressures)
- Operating cash flow trends and cash conversion rates relative to earnings quality
- Product pipeline diversity and development stage to assess long-term growth drivers beyond current products
- Capital allocation decisions regarding debt, share buybacks, or M&A activity
CRMD Financial Metrics
💡 AI Analyst Insight
The 55.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.11x current ratio provides a solid financial cushion.
CRMD Profitability Ratios
CRMD vs Healthcare Sector
How CorMedix Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRMD Balance Sheet & Liquidity
CRMD 5-Year Financial Trend
5-Year Trend Summary: CorMedix Inc.'s revenue has grown significantly by 130,196% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
CRMD Growth Metrics (YoY)
CRMD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.5M | -$2.8M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRMD Capital Allocation
CRMD SEC Filings
Access official SEC EDGAR filings for CorMedix Inc. (CIK: 0001410098)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRMD
What is the AI rating for CRMD?
CorMedix Inc. (CRMD) has an AI rating of STRONG BUY with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRMD's key strengths?
Explosive revenue and earnings growth (617% and 1009% YoY respectively) indicating strong product market fit and demand. Exceptional profitability with 52.3% net margin and 40.2% ROE, well above pharmaceutical industry averages.
What are the risks of investing in CRMD?
Extreme growth rates (617% revenue, 1009% net income) may not be sustainable; requires investigation into growth drivers and market saturation potential. High concentration of revenue likely tied to specific product(s); product obsolescence or competitive displacement poses significant downside risk.
What is CRMD's revenue and growth?
CorMedix Inc. reported revenue of $311.7M.
Does CRMD pay dividends?
CorMedix Inc. does not currently pay dividends.
Where can I find CRMD SEC filings?
Official SEC filings for CorMedix Inc. (CIK: 0001410098) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRMD's EPS?
CorMedix Inc. has a diluted EPS of $2.04.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.